Pimecrolimus Cream
Product Images NDC 0591-2944

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Pimecrolimus (NDC 0591-2944). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

The Structural Formula Of Pimecrolimus Is (1r,9s,12s,13r,14s,17r,18e,21s,23s,24r,25s,27r)-12-[(1e)-2-{(1r,3r,4s)-4-chloro-3-methoxycyclohexyl}-1-methylvinyl]-17-ethyl-1,14-dihydroxy-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetraone. The Compound Has The Molecular Formula C43h68cino11 And The Molecular Weight Of 810.47. (Pimecrolimus Cream A209345 1)

The Structural Formula Of Pimecrolimus Is (1r,9s,12s,13r,14s,17r,18e,21s,23s,24r,25s,27r)-12-[(1e)-2-{(1r,3r,4s)-4-chloro-3-methoxycyclohexyl}-1-methylvinyl]-17-ethyl-1,14-dihydroxy-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetraone. The Compound Has The Molecular Formula C43h68cino11 And The Molecular Weight Of 810.47. (Pimecrolimus Cream A209345 1)
Chemical structure diagram of pimecrolimus, the active ingredient in pimecrolimus cream 10 mg/g. The molecular structure is depicted with labeled atoms and bonds, illustrating the compound's chemical composition as submitted in the FDA Structured Product Labeling.*
FDA Label Image

Figure 1 Depicts The Time Course Of Improvement In The Percent Body Surface Area Affected As A Result Of Treatment With Pimecrolimus Cream, 1% In 2 To 17 Year Olds. (Pimecrolimus Cream A209345 2)

Figure 1 Depicts The Time Course Of Improvement In The Percent Body Surface Area Affected As A Result Of Treatment With Pimecrolimus Cream, 1% In 2 To 17 Year Olds. (Pimecrolimus Cream A209345 2)
A line graph titled 'Body Surface Area Over Time' showing percent body surface area affected over 43 days. It compares pimecrolimus 1% (marked with diamonds and a solid line) and vehicle (marked with squares and a dashed line). The graph includes error bars representing mean ± 95% confidence intervals.*
FDA Label Image

Figure 2 Shows The Time Course Of Improvement In Erythema As A Result Of Treatment With Pimecrolimus Cream, 1% In 2 To 17 Year Olds. (Pimecrolimus Cream A209345 3)

Figure 2 Shows The Time Course Of Improvement In Erythema As A Result Of Treatment With Pimecrolimus Cream, 1% In 2 To 17 Year Olds. (Pimecrolimus Cream A209345 3)
A line graph titled "Mean Erythema Over Time" showing mean erythema scores with 95% confidence intervals on the y-axis and time in days on the x-axis. Two data series are presented: one for pimecrolimus 1% and one for the vehicle, illustrating changes in erythema scores over a 43-day period.*
FDA Label Image

1 (Pimecrolimus Cream A209345 4)

1 (Pimecrolimus Cream A209345 4)
Label for Pimecrolimus Cream, 1%, a topical prescription cream by Actavis Pharma, Inc. The label includes the proprietary and generic name, strength, usage instructions, inactive ingredients, net weight of 30 grams, and multiple barcodes. It specifies the NDC 0591-2944-30 and detailed storage and usage information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.